metformin has been researched along with Inflammatory Bowel Diseases in 12 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Inflammatory Bowel Diseases: Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Drug-induced gastrointestinal disorders can mimic conditions, such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and, hence, recognition can prevent unnecessary investigations and treatment." | 2.50 | Drug-induced gastrointestinal disorders. ( Gibson, PR; Lubel, J; Nandurkar, S; Philpott, HL, 2014) |
| "Metformin has pleiotropic effects including anti-inflammatory properties and effects on the gut microbiome." | 1.72 | Metformin use is not associated with reduced risk of older onset inflammatory bowel disease: a Danish nationwide population-based study. ( Allin, KH; Jacobsen, RK; Jensen, CB; Jess, T, 2022) |
| " A dose-response pattern was observed while comparing the tertiles of cumulative duration of metformin therapy to never users." | 1.62 | Metformin Use Is Associated with a Lower Risk of Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus. ( Tseng, CH, 2021) |
| " Many researchers have reported immune-mediated adverse events induced by immune checkpoint inhibitors (ICI) single agent." | 1.51 | Inflammatory bowel disease associated with the combination treatment of nivolumab and metformin: data from the FDA adverse event reporting system. ( Liu, J; Zhang, L; Zhang, Y; Zhou, H, 2019) |
| "Treatment with metformin inhibited the expression of interleukin (IL)-17, p-STAT3, and p-mTOR." | 1.42 | Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance. ( Cho, ML; Kim, EK; Kim, JK; Lee, SH; Lee, SY; Shin, DY; Yang, EJ, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 6 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takahara, M | 1 |
| Takaki, A | 1 |
| Hiraoka, S | 1 |
| Takei, K | 1 |
| Yasutomi, E | 1 |
| Igawa, S | 1 |
| Yamamoto, S | 1 |
| Oka, S | 1 |
| Ohmori, M | 1 |
| Yamasaki, Y | 1 |
| Inokuchi, T | 1 |
| Kinugasa, H | 1 |
| Harada, K | 1 |
| Udono, H | 1 |
| Okada, H | 1 |
| Allin, KH | 1 |
| Jensen, CB | 1 |
| Jacobsen, RK | 1 |
| Jess, T | 1 |
| Ikhar, AS | 1 |
| Kolte, RA | 1 |
| Kolte, AP | 1 |
| Purohit, AR | 1 |
| Dahake, RN | 1 |
| Wanchaitanawong, W | 1 |
| Thinrungroj, N | 1 |
| Chattipakorn, SC | 1 |
| Chattipakorn, N | 1 |
| Shinlapawittayatorn, K | 1 |
| Tseng, CH | 1 |
| Yang, S | 1 |
| Park, JS | 1 |
| Hwang, SH | 1 |
| Cho, KH | 1 |
| Na, HS | 1 |
| Choi, J | 1 |
| Jhun, J | 1 |
| Kim, SJ | 1 |
| Lee, BI | 1 |
| Park, SH | 1 |
| Cho, ML | 2 |
| Wu, W | 1 |
| Wang, S | 1 |
| Liu, Q | 1 |
| Shan, T | 1 |
| Wang, Y | 1 |
| Zhou, H | 1 |
| Liu, J | 1 |
| Zhang, Y | 1 |
| Zhang, L | 1 |
| Kim, SC | 1 |
| Schneeweiss, S | 1 |
| Glynn, RJ | 1 |
| Doherty, M | 1 |
| Goldfine, AB | 1 |
| Solomon, DH | 1 |
| Philpott, HL | 1 |
| Nandurkar, S | 1 |
| Lubel, J | 1 |
| Gibson, PR | 1 |
| Lee, SY | 1 |
| Lee, SH | 1 |
| Yang, EJ | 1 |
| Kim, EK | 1 |
| Kim, JK | 1 |
| Shin, DY | 1 |
| Haq, S | 1 |
| Ali, S | 1 |
| Mohammad, R | 1 |
| Sarkar, FH | 1 |
4 reviews available for metformin and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Efficacy of platelet rich fibrin with and without metformin in the treatment of periodontal osseous defects: a systematic review and meta-analysis.
Topics: Alveolar Bone Loss; Humans; Inflammatory Bowel Diseases; Metformin; Periodontal Attachment Loss; Pla | 2023 |
Repurposing metformin as a potential treatment for inflammatory bowel disease: Evidence from cell to the clinic.
Topics: Anti-Inflammatory Agents; Biological Factors; Colitis, Ulcerative; Drug Repositioning; Humans; Infla | 2022 |
Drug-induced gastrointestinal disorders.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antipsychotic Agents; Drug Administr | 2014 |
The complexities of epidemiology and prevention of gastrointestinal cancers.
Topics: Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Diabetes Complications; Folic Acid; Gastrointesti | 2012 |
8 other studies available for metformin and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Metformin ameliorates chronic colitis in a mouse model by regulating interferon-γ-producing lamina propria CD4
Topics: Adoptive Transfer; AMP-Activated Protein Kinases; Animals; CD4-Positive T-Lymphocytes; Colitis; Colo | 2022 |
Metformin use is not associated with reduced risk of older onset inflammatory bowel disease: a Danish nationwide population-based study.
Topics: Aged; Anti-Inflammatory Agents; Case-Control Studies; Colitis, Ulcerative; Denmark; Dipeptidyl-Pepti | 2022 |
Metformin Use Is Associated with a Lower Risk of Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Databases, Factual; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Duration of T | 2021 |
Metformin-Inducible Small Heterodimer Partner Interacting Leucine Zipper Protein Ameliorates Intestinal Inflammation.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Epithelial Cells; Female; Gene Expression Regulat | 2021 |
Metformin Protects against LPS-Induced Intestinal Barrier Dysfunction by Activating AMPK Pathway.
Topics: Administration, Oral; AMP-Activated Protein Kinases; Animals; Disease Models, Animal; Humans; Inflam | 2018 |
Inflammatory bowel disease associated with the combination treatment of nivolumab and metformin: data from the FDA adverse event reporting system.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Age | 2019 |
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2015 |
Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance.
Topics: Animals; Cell Differentiation; Cell Line; Cytokines; Disease Models, Animal; Gene Expression; Humans | 2015 |